Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital Schleswig Holstein, Campus Lübeck, in Germany.
Axel Merseburger, MD
Advertisement
Axel Merseburger, MD, is a professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.
Articles by Axel Merseburger, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5